CRP apheresis registry for COVID-19

Recruiting

• Conditions: COVID-19 disease; U09; Post COVID-19 condition

• Registration Number: DRKS00024376
• Lead Sponsor: Pentracor GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-04
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

COVID-19, CRP-apheresis

Exclusion Criteria

none

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CRP progression

Secondary Outcome Measures

Name	Time	Method
Length of stay in hospital<br>- Length of stay in the intensive care unit<br>- Days of mandatory ventilation<br>- mortality<br>- Pulmonary tissue damage<br>- Myocardial tissue damage<br>- Inflammation markers<br>- Incidence of adverse effects of CRP apheresis